

Suzanne C O'Neill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2366981/publications.pdf>

Version: 2024-02-01

35
papers

382
citations

840776

11
h-index

839539

18
g-index

35
all docs

35
docs citations

35
times ranked

622
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2006, 142C, 251-259. | 1.6 | 61 |
| 2 | Cost Effectiveness of Gene Expression Profile Testing in Community Practice. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-562. | 1.6 | 35 |
| 3 | Mammographic Breast Density as a Risk Factor for Breast Cancer: Awareness in a Recently Screened Clinical Sample. <i>Women's Health Issues</i> , 2014, 24, e321-e326. | 2.0 | 29 |
| 4 | BRCA1/2 test results impact risk management attitudes, intentions, and uptake. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 755-764. | 2.5 | 25 |
| 5 | Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. <i>Cancer</i> , 2015, 121, 4062-4070. | 4.1 | 21 |
| 6 | Primary care providers' willingness to recommend BRCA1/2 testing to adolescents. <i>Familial Cancer</i> , 2010, 9, 43-50. | 1.9 | 18 |
| 7 | Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1216-1224. | 4.9 | 17 |
| 8 | Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS. <i>Journal of Cancer Epidemiology</i> , 2012, 2012, 1-8. | 1.1 | 14 |
| 9 | A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. <i>Contemporary Clinical Trials</i> , 2017, 56, 25-33. | 1.8 | 14 |
| 10 | Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel population. <i>Familial Cancer</i> , 2018, 17, 351-360. | 1.9 | 13 |
| 11 | The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families. <i>Journal of Cancer Education</i> , 2021, 36, 72-84. | 1.3 | 13 |
| 12 | Between-Race Differences in Supplemental Breast Cancer Screening Before and After Breast Density Notification Law. <i>Journal of the American College of Radiology</i> , 2019, 16, 797-803. | 1.8 | 12 |
| 13 | Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes. <i>JCO Oncology Practice</i> , 2020, 16, e1085-e1097. | 2.9 | 11 |
| 14 | Oncologist and organizational factors associated with variation in breast cancer multigene testing. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 167-176. | 2.5 | 10 |
| 15 | A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer. <i>Breast</i> , 2022, 61, 43-57. | 2.2 | 9 |
| 16 | Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 549-555. | 2.5 | 8 |
| 17 | Prior breast density awareness, knowledge, and communication in a health system-embedded behavioral intervention trial. <i>Cancer</i> , 2020, 126, 1614-1621. | 4.1 | 8 |
| 18 | Survey on Addressing the Information and Support Needs of Jewish Women at Increased Risk for or Diagnosed with Breast Cancer: The Sharsheret Experience. <i>Healthcare (Switzerland)</i> , 2015, 3, 324-337. | 2.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Patterns of 21-Gene Assay Testing and Chemotherapy Use in Black and White Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2015, 15, e83-e92. | 2.4 | 7 |
| 20 | Cancer genetic health communication in families tested for hereditary breast/ovarian cancer risk: a qualitative investigation of impact on children's genetic health literacy and psychosocial adjustment. <i>Translational Behavioral Medicine</i> , 2019, 9, 493-503. | 2.4 | 7 |
| 21 | Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. <i>Journal of Clinical Oncology</i> , 2021, 39, 2893-2902. | 1.6 | 7 |
| 22 | Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives. <i>Journal of Health Communication</i> , 2018, 23, 679-686. | 2.4 | 5 |
| 23 | Underuse of exon mutational analysis for gastrointestinal stromal tumors. <i>Journal of Surgical Research</i> , 2018, 231, 43-48. | 1.6 | 4 |
| 24 | The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 417-427. | 2.5 | 4 |
| 25 | Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa114. | 2.9 | 4 |
| 26 | Characteristics Associated with Participation in ENGAGED 2 – A Web-based Breast Cancer Risk Communication and Decision Support Trial. , 2020, 24, 1-4. | | 4 |
| 27 | Facilitators of peer coaching/support engagement and dissemination among women at risk for and surviving with breast cancer. <i>Translational Behavioral Medicine</i> , 2021, 11, 153-160. | 2.4 | 3 |
| 28 | Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar. <i>Patient Education and Counseling</i> , 2021, 104, 250-256. | 2.2 | 3 |
| 29 | Physicians' perceptions of breast density notification laws and appropriate patient follow-up. <i>Breast Journal</i> , 2021, 27, 586-594. | 1.0 | 3 |
| 30 | Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz062. | 2.9 | 2 |
| 31 | Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off. <i>Patient</i> , 2020, 13, 557-566. | 2.7 | 2 |
| 32 | Using Protection Motivation Theory to Predict Intentions for Breast Cancer Risk Management: Intervention Mechanisms from a Randomized Controlled Trial. <i>Journal of Cancer Education</i> , 2023, 38, 292-300. | 1.3 | 2 |
| 33 | The Front Line of Genomic Translation. <i>Journal of Cancer Epidemiology</i> , 2012, 2012, 1-3. | 1.1 | 0 |
| 34 | Effect of a Randomized Trial of a Web-Based Intervention on Patient-Provider Communication About Breast Density. <i>Journal of Women's Health</i> , 2021, 30, 1529-1537. | 3.3 | 0 |
| 35 | Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis. <i>Psycho-Oncology</i> , 2022, 31, 788-797. | 2.3 | 0 |